-
With FDA nod, Sanofi's Wayrilz becomes 1st US BTK drug approved for immune thrombocytopenia
30 Aug 2025 03:48 GMT
… biotech has made it across the FDA finish line first.
The drug … —the cells that allow blood to clot—can lead … ) receptor agonists, such as Amgen’s Nplate or Novartis’ Promacta. Roche … with Principia as a potential treatment for multiple sclerosis (MS). …
-
Impact of Primary Chronic Immune Thrombocytopenia and Thrombopoietin Receptor Agonists Treatment Instructions on Daily Living: Results of a Multinational Cross-Sectional Survey
12 Aug 2025 21:08 GMT
… treatment of people with ITP in most global countries: romiplostim (Nplate®, Amgen … about treatment was most commonly received via a doctor ( … dependent on corticosteroid treatment. Blood. 2021;137(20 … Drugs and Medical Devices. DRKS - German Clinical Trials …
-
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy
30 May 2025 12:24 GMT
…
(Reuters) -Amgen’s Nplate, which treats low blood platelet counts caused … patients in the pivotal trial had either colorectal, gastroesophageal … who could benefit from treatment with drugs that target the … for larger late-stage trials to confirm the results …
-
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia
02 Jun 2025 17:07 GMT
… Nplate was first approved by the US Food and Drug Administration (FDA … to alternative treatments.
GlobalData predicts Nplate will generate … the parent company of Pharmaceutical Technology.
The therapy … count in the blood, weaken blood clotting, and raise …
-
U.S. Orphan Designated Drugs Market Research Report 2025: $190 Billion Opportunities, Drugs Sales, Price, Dosage & Clinical Trials Insights to 2030 - ResearchAndMarkets.com
19 May 2025 18:48 GMT
… and biotechnology.
Key Topics Covered:
1. FDA Orphan … Pharmaceutical Companies
5. US Orphan Designated Drugs Clinical Trials … Drugs Dosage, Price & Treatment Cost Insight
8.1 Lynparza
8.2 Nplate … Onyx Pharmaceuticals (Amgen)
10.49 Otsuka Pharmaceutical
10. …
-
Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight
15 Sep 2025 17:00 GMT
… purpura medications are … Drug Administration (FDA) has approved DOPTELET (avatrombopag) for the treatment … ;TAVLESSE, DOPTELET, NPLATE/ROMIPLATE, … Pharmaceuticals, Kissei Pharmaceutical, Grifols, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen …
-
Amgen Inc. (NASDAQ:AMGN) Q1 2025 Earnings Call Transcript
02 May 2025 13:09 GMT
… cardiovascular outcomes trial. In bone health, Amgen is the … LUMAKRAS, Vectibix, KYPROLIS, Nplate and XGEVA grew 10% year … initiating multiple Phase III trials of MariTide and TEZSPIRE … CD19 directed BiTE medicine BLINCYTO in earlier treatment settings, while …
-
Nplate, Romiplate Romiplostim Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034
18 Mar 2025 12:54 GMT
… treatment approaches
oDevelopment of effective therapies for blood … treatment protocols
oIntegration of technology in drug development
oInnovative drug … in medical … Nplate, Romiplate Romiplostim market include Novartis AG, Amgen, and Intas Pharmaceuticals …
-
October - December 2020 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
05 Mar 2025 21:57 GMT
… Pharma Solutions for Perrigo Pharmaceutical Company at the … Patient Counseling Information”, and “Medication Guide” sections of the … aminolevulinic acid hydrochloride
Hypersensitivity
FDA is evaluating the … of drug available in the vial with overfill.
Nplate …
-
3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs
26 Feb 2025 00:30 GMT
… 152 stocks in the Medical – Pharmaceuticals industry, it is ranked … cardiometabolic treatments, with multiple small-molecule drug candidates …
Amgen Inc. (AMGN)
AMGN is a global biotechnology company … Otezla, Prolia, Xgeva, Nplate, Kyprolis, Blincyto etc.
On …